LGD-4033 or testosterone for a first cycle?

Testosterone, for the scientific base and functional coverage. LGD-4033 has a limited human corpus (Basaria 2013 phase 1 only) and incomplete androgenic coverage that can cause mid-cycle libido drop. Testosterone has been clinically validated for decades, its response is predictable, and it covers all dimensions of androgenic function. First clean cycle: enanthate or cypionate 400 mg/week × 12 weeks, titrated AI, classic PCT. LGD-4033 addition considerable on 2nd or 3rd cycle.

Does LGD-4033 suppress as much as exogenous testosterone?

Comparable but more modest at recreational doses. Exogenous testosterone at 400 mg/week suppresses 95-100% of endogenous production. LGD-4033 at 10 mg/d × 8 weeks suppresses 50-70% per Basaria 2013 and user reports. Practical effect: both require PCT, but recovery under LGD-4033 is typically faster (4-6 weeks vs 8-12 for supraphysiological testosterone). Biological panel post-PCT confirms recovery.

Can you run an LGD-4033 cycle without PCT?

Inadvisable. Even at 5 mg/d × 8 weeks, endogenous testo suppression is measurable (30-40%) and recovery without pharmacological support takes 8-12 weeks vs 4-6 with PCT. The cost of a PCT (nolvadex 20 € for 4 weeks) is negligible compared to hormonal comfort during recovery. Practical rule: any SARM at anabolic dose requires a PCT.

How much gains with LGD-4033 vs testosterone?

For comparable exposure time (8 weeks): LGD-4033 10 mg/d ≈ +3-5 kg net lean mass retained. Testosterone 400 mg/week ≈ +5-7 kg. Testosterone produces more raw gains but with more marked water retention. LGD-4033 produces more modest but drier gains. At retained gains 3 months post-PCT, the difference narrows to +2-3 kg in favor of testosterone. For user evaluating gains/effort/risks, testosterone remains better ratio.

Does LGD-4033 cause transaminase elevation?

Possible in 5-15% of users at 10 mg/d × 8 wk. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects. The toxicity is not 17α-alkylated (different from classic oral AAS) but distinct hepatic aggression pathway. ALT/AST monitoring at W0, W4, W8 essential. Stop if elevation > 3× normal. Lab tests on the product before cycle (possible impurities in underground SARMs).

Does LGD-4033 improve libido?

Variable and often disappointing. Like RAD-140, LGD-4033 suppresses endogenous testo without functionally replacing it at the complete androgenic level (cerebral androgen receptor and DHT conversion are not activated the same way). Result: many users report libido drop after W3-W4. Possible compensation by moderate-dose testosterone (200 mg/week) or proviron 50 mg/d in parallel.

What PCT after LGD-4033?

Start 3-4 days after last intake. Standard scheme: nolvadex 20 mg/d × 4 weeks. If high dose (10 mg/d × 8+ weeks) or marked mid-cycle suppression: clomid 50/25/25/25 mg + nolvadex 20/20/10/10 mg × 4-6 weeks. T total, LH, FSH panel at W4 post-PCT. If T < 300 ng/dL, extend 2 additional weeks. No hCG needed in SARM solo.

Does LGD-4033 increase transaminases?

Possible in 5-15% of users at 10 mg/d × 8 wk. Typically moderate elevations (1.5-3× normal) and reversible on cessation. More severe DILI cases reported but rare. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects or under products of variable purity. ALT/AST monitoring at W0, W4, W8 essential. If elevation > 3× normal, immediate stop with weekly check until normalization.

LGD-4033 vs Testosterone: complete comparison (SARM vs AAS, dosing, profile)

Q: Does LGD-4033 increase transaminases?

Possible in 5-15% of users at 10 mg/d × 8 wk. Typically moderate elevations (1.5-3× normal) and reversible on cessation. More severe DILI cases reported but rare. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects or under products of variable purity. ALT/AST monitoring at W0, W4, W8 essential. If elevation > 3× normal, immediate stop with weekly check until normalization.

Critère	lgd-4033	testosterone
Class	Non-steroidal SARM	Steroidal AAS (reference)
Route	Oral (daily)	Injectable (1-2× per week)
Aromatization	No	Yes (to E2)
Human studies	Phase 1 (Basaria 2013)	Multiple decades of RCTs
Libido effect	Variable (often negative)	Covering
HPG suppression	Moderate to strong	Strong
Typical dose	5-10 mg/d	300-600 mg/week
Hepatotoxicity	Possible moderate	Low (injection)

Quand choisir lgd-4033

LGD-4033 (ligandrol) is the most studied SARM in humans: Basaria 2013 (phase 1, 76 subjects, 1 mg/d × 21 days) demonstrated +1.2 kg of dose-dependent lean mass with acceptable short-term tolerance profile. Choose it for: (1) a first SARM cycle oriented toward lean mass, (2) an oral alternative to injectable AAS for users wanting to avoid injections, (3) a 'bridge' cycle between testosterone cycles to maintain gains with moderate HPG suppression, (4) a user looking to avoid aromatization, acne and hair loss specific to classic AAS. Pharmacological profile (Solomon 2019, Bhasin 2009): non-steroidal so muscular selectivity, no aromatization, no prostatic 5α-reduction, long half-life (24-36 h) allowing single daily intake. Drawbacks to anticipate (Pope 2014, Endocrine Society): moderate to strong dose-dependent HPG suppression (50-70% of endogenous testo at 10 mg/d × 8 weeks), PCT required even in short cycle, possible ALT/AST elevations (5-15% of users), slightly degraded lipid profile (HDL down), incomplete androgenic coverage at functional level (frequent libido drop mid-cycle, to compensate by moderate testo base). Typical dose 5-10 mg/d × 6-8 weeks, single morning intake with or without food. PCT nolvadex 20 mg/d × 4 weeks. Not suited for women (virilization possible) nor adolescents (impact on hormonal maturation). Human corpus still limited compared to testosterone (Basaria 2013 remains the flagship study).

Quand choisir testosterone

Exogenous testosterone is the absolute reference molecule: Bhasin 1996 (NEJM, RCT 600 mg/week × 10 weeks, +6.1 kg lean mass and +22% bench press strength), Bhasin 2001 (linear dose-response), Bhasin 2018 (Endocrine Society TRT guideline). Choose it for: (1) a first cycle where scientific base matters, (2) any cycle aiming at complete androgenic coverage (libido, energy, bone density), (3) clinically supervised TRT, (4) the base of any more advanced AAS stack. Pharmacological profile: complete androgen (ratio 100:100), aromatization controllable by AI, half-life variable by ester (enanthate 4.5 d, cypionate ~8 d). Drawbacks: injections required, aromatization to manage, marked androgenic profile (possible acne, hair loss), complete HPG suppression. But no compound has a more solid safety corpus nor a more complete functional coverage. For advanced users, 400-600 mg/week in 12-16 wk cycle. For TRT, 100-150 mg/week. PCT clomid + nolvadex 4-6 weeks after cycle (Rahnema 2014).

Combinaison ?

The LGD-4033 + testosterone combo is widespread among users wanting to add a light oral to an injectable cycle. Scheme: testosterone 300-400 mg/week + LGD-4033 5-10 mg/d × 8-10 weeks. Testosterone ensures complete androgenic coverage (libido, energy, bone density) that LGD-4033 cannot provide alone at recreational dose. LGD-4033 modestly amplifies anabolic gains without stacking aromatization (LGD-4033 does not aromatize, unlike testosterone at 500+ mg/week). Dose-dependent AI (anastrozole 0.5 mg 2× per week), titrated on E2 measured at W2 and W6. Complete monitoring: T total, LH, FSH, ALT/AST, lipids, CBC at W0, W4, W8. Classic PCT 2-3 weeks after last testosterone injection, with hCG 1500 IU EOD × 10 days then SERM (clomid 50/25/25/25 or nolvadex 40/20/20/20) × 4-6 weeks. Complete panel at W6 post-PCT to confirm recovery. The combination does not bring significantly superior anabolic gains over testosterone alone at 500 mg/week — the main interest is being able to use a moderate testo dose while keeping a visible stack effect and a milder cutaneous androgenic profile. Sample 10-week hybrid timeline: W0 baseline complete hormonal panel, W1 testo + LGD-4033 start, W2 first BP and ALT/AST check, W4 measured E2 and AI titration, W6 mid-cycle full panel including lipids, W8 LGD-4033 stop (8 weeks of cumulative oral exposure max), W10 last testo injection, W12 PCT start (testo-timed at 14 days), W20 post-PCT recovery confirmation. The benefit of running LGD-4033 with moderate-dose testo (300 mg/week) instead of high-dose testo alone is the milder cutaneous androgenic profile (less acne, less hair loss). Independent lab testing for LGD-4033 authenticity: send 100 mg to Janoshik (~50 €) before cycle to confirm dose. The SARM market has 40-60% mislabeling per analyses.

FAQ

LGD-4033 or testosterone for a first cycle?: Testosterone, for the scientific base and functional coverage. LGD-4033 has a limited human corpus (Basaria 2013 phase 1 only) and incomplete androgenic coverage that can cause mid-cycle libido drop. Testosterone has been clinically validated for decades, its response is predictable, and it covers all dimensions of androgenic function. First clean cycle: enanthate or cypionate 400 mg/week × 12 weeks, titrated AI, classic PCT. LGD-4033 addition considerable on 2nd or 3rd cycle.
Does LGD-4033 suppress as much as exogenous testosterone?: Comparable but more modest at recreational doses. Exogenous testosterone at 400 mg/week suppresses 95-100% of endogenous production. LGD-4033 at 10 mg/d × 8 weeks suppresses 50-70% per Basaria 2013 and user reports. Practical effect: both require PCT, but recovery under LGD-4033 is typically faster (4-6 weeks vs 8-12 for supraphysiological testosterone). Biological panel post-PCT confirms recovery.
Can you run an LGD-4033 cycle without PCT?: Inadvisable. Even at 5 mg/d × 8 weeks, endogenous testo suppression is measurable (30-40%) and recovery without pharmacological support takes 8-12 weeks vs 4-6 with PCT. The cost of a PCT (nolvadex 20 € for 4 weeks) is negligible compared to hormonal comfort during recovery. Practical rule: any SARM at anabolic dose requires a PCT.
How much gains with LGD-4033 vs testosterone?: For comparable exposure time (8 weeks): LGD-4033 10 mg/d ≈ +3-5 kg net lean mass retained. Testosterone 400 mg/week ≈ +5-7 kg. Testosterone produces more raw gains but with more marked water retention. LGD-4033 produces more modest but drier gains. At retained gains 3 months post-PCT, the difference narrows to +2-3 kg in favor of testosterone. For user evaluating gains/effort/risks, testosterone remains better ratio.
Does LGD-4033 cause transaminase elevation?: Possible in 5-15% of users at 10 mg/d × 8 wk. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects. The toxicity is not 17α-alkylated (different from classic oral AAS) but distinct hepatic aggression pathway. ALT/AST monitoring at W0, W4, W8 essential. Stop if elevation > 3× normal. Lab tests on the product before cycle (possible impurities in underground SARMs).
Does LGD-4033 improve libido?: Variable and often disappointing. Like RAD-140, LGD-4033 suppresses endogenous testo without functionally replacing it at the complete androgenic level (cerebral androgen receptor and DHT conversion are not activated the same way). Result: many users report libido drop after W3-W4. Possible compensation by moderate-dose testosterone (200 mg/week) or proviron 50 mg/d in parallel.
What PCT after LGD-4033?: Start 3-4 days after last intake. Standard scheme: nolvadex 20 mg/d × 4 weeks. If high dose (10 mg/d × 8+ weeks) or marked mid-cycle suppression: clomid 50/25/25/25 mg + nolvadex 20/20/10/10 mg × 4-6 weeks. T total, LH, FSH panel at W4 post-PCT. If T < 300 ng/dL, extend 2 additional weeks. No hCG needed in SARM solo.
Does LGD-4033 increase transaminases?: Possible in 5-15% of users at 10 mg/d × 8 wk. Typically moderate elevations (1.5-3× normal) and reversible on cessation. More severe DILI cases reported but rare. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects or under products of variable purity. ALT/AST monitoring at W0, W4, W8 essential. If elevation > 3× normal, immediate stop with weekly check until normalization.

LGD-4033 vs Testosterone: complete comparison (SARM vs AAS, dosing, profile)

Critère	lgd-4033	testosterone
Class	Non-steroidal SARM	Steroidal AAS (reference)
Route	Oral (daily)	Injectable (1-2× per week)
Aromatization	No	Yes (to E2)
Human studies	Phase 1 (Basaria 2013)	Multiple decades of RCTs
Libido effect	Variable (often negative)	Covering
HPG suppression	Moderate to strong	Strong
Typical dose	5-10 mg/d	300-600 mg/week
Hepatotoxicity	Possible moderate	Low (injection)

Quand choisir lgd-4033

Quand choisir testosterone

Combinaison ?

FAQ

LGD-4033 or testosterone for a first cycle?: Testosterone, for the scientific base and functional coverage. LGD-4033 has a limited human corpus (Basaria 2013 phase 1 only) and incomplete androgenic coverage that can cause mid-cycle libido drop. Testosterone has been clinically validated for decades, its response is predictable, and it covers all dimensions of androgenic function. First clean cycle: enanthate or cypionate 400 mg/week × 12 weeks, titrated AI, classic PCT. LGD-4033 addition considerable on 2nd or 3rd cycle.
Does LGD-4033 suppress as much as exogenous testosterone?: Comparable but more modest at recreational doses. Exogenous testosterone at 400 mg/week suppresses 95-100% of endogenous production. LGD-4033 at 10 mg/d × 8 weeks suppresses 50-70% per Basaria 2013 and user reports. Practical effect: both require PCT, but recovery under LGD-4033 is typically faster (4-6 weeks vs 8-12 for supraphysiological testosterone). Biological panel post-PCT confirms recovery.
Can you run an LGD-4033 cycle without PCT?: Inadvisable. Even at 5 mg/d × 8 weeks, endogenous testo suppression is measurable (30-40%) and recovery without pharmacological support takes 8-12 weeks vs 4-6 with PCT. The cost of a PCT (nolvadex 20 € for 4 weeks) is negligible compared to hormonal comfort during recovery. Practical rule: any SARM at anabolic dose requires a PCT.
How much gains with LGD-4033 vs testosterone?: For comparable exposure time (8 weeks): LGD-4033 10 mg/d ≈ +3-5 kg net lean mass retained. Testosterone 400 mg/week ≈ +5-7 kg. Testosterone produces more raw gains but with more marked water retention. LGD-4033 produces more modest but drier gains. At retained gains 3 months post-PCT, the difference narrows to +2-3 kg in favor of testosterone. For user evaluating gains/effort/risks, testosterone remains better ratio.
Does LGD-4033 cause transaminase elevation?: Possible in 5-15% of users at 10 mg/d × 8 wk. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects. The toxicity is not 17α-alkylated (different from classic oral AAS) but distinct hepatic aggression pathway. ALT/AST monitoring at W0, W4, W8 essential. Stop if elevation > 3× normal. Lab tests on the product before cycle (possible impurities in underground SARMs).
Does LGD-4033 improve libido?: Variable and often disappointing. Like RAD-140, LGD-4033 suppresses endogenous testo without functionally replacing it at the complete androgenic level (cerebral androgen receptor and DHT conversion are not activated the same way). Result: many users report libido drop after W3-W4. Possible compensation by moderate-dose testosterone (200 mg/week) or proviron 50 mg/d in parallel.
What PCT after LGD-4033?: Start 3-4 days after last intake. Standard scheme: nolvadex 20 mg/d × 4 weeks. If high dose (10 mg/d × 8+ weeks) or marked mid-cycle suppression: clomid 50/25/25/25 mg + nolvadex 20/20/10/10 mg × 4-6 weeks. T total, LH, FSH panel at W4 post-PCT. If T < 300 ng/dL, extend 2 additional weeks. No hCG needed in SARM solo.
Does LGD-4033 increase transaminases?: Possible in 5-15% of users at 10 mg/d × 8 wk. Typically moderate elevations (1.5-3× normal) and reversible on cessation. More severe DILI cases reported but rare. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects or under products of variable purity. ALT/AST monitoring at W0, W4, W8 essential. If elevation > 3× normal, immediate stop with weekly check until normalization.